Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival

  • Published:
International journal of pancreatology Aims and scope Submit manuscript

Summary

For the purpose of determining the prognostic significance of HER2/neu oncogene in pancreatic and ampullary cancers, 21 pancreatic cancers of ductal origin and six cancers of the ampulla of Vater were studied immunohistochemically using the monoclonal antibody (MAb) CB11, specifically reactive with HER2/neu product. Staining of the epithelium of the normal duct and acini was negative or weakly positive. Moderately and strongly positive reactions indicated the overexpression of this gene, and were found in 10 of 21 (47.6%) pancreatic cancers of ductal origin and in 2 of 6 (33.3%) ampullary adenocarcinomas. Overexpression of HER2/neu was closely and inversely related to the survival of the patients with pancreatic cancer of ductal origin: 19.1±11.7 mo for those not overexpressing vs 7.3±3.8 mo for the overexpressors (p<0.01). Among the pancreatic cancer group, 11 patients underwent cancer resection. The average survival for the 7 with nonoverexpressing cancer was 21.4±14.3 mo vs 10.5±3.6 mo for those with the overexpressing tumor. Among those not undergoing resection, the average survival for the 4 with nonoverexpressing cancer was 15.0 ±3.8 mo as contrasted to 5.2±2.1 mo for the overexpressors (p<0.01). Although the number of patients is small, these findings duggest that the overexpression of HER2/neu gene product may be frequently found in pancreatic cancer of ductal origin and may be one of the useful prognostic biomarkers for this cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society.Cancer Facts and Figures—1991. The American Cancer Society, Inc., Atlanta, GA, 1991.

    Google Scholar 

  2. Cubilla AL, Fitzgerald PJ, Fortner JG. Pancreas cancerduct cell adenocarcinoma: survival in relation to site, size, stage, and type of therapy.J Surg Oncol 1978; 10: 465–487.

    Article  PubMed  CAS  Google Scholar 

  3. Trede M. The surgical treatment of pancreatic carcinoma.Surgery 1985; 97: 28–35

    PubMed  CAS  Google Scholar 

  4. Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M, Block GE. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas and distal common bile duct.Ann Surg 1989; 210: 544–554.

    Article  PubMed  CAS  Google Scholar 

  5. Grace PA, Pitt HA, Tompkins PK, et al. Decreased morbidity and mortality after pancreatoduodenectomy.Am J Surg 1986; 151: 141–149.

    Article  PubMed  CAS  Google Scholar 

  6. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure.Ann Surg 1987; 206: 358–365.

    Article  PubMed  CAS  Google Scholar 

  7. Warshaw AL, Swanson RS. Pancreas cancer in 1988; possibilities and probabilities.Ann Surg 1988; 208: 541–553.

    Article  PubMed  CAS  Google Scholar 

  8. Pellegrini CA, Heck CF, Raper S, Way LW. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy.Arch Surg 1989; 124: 778–781.

    PubMed  CAS  Google Scholar 

  9. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions withneu.J Steroid Biochem 1989; 34: 123–131.

    Article  PubMed  CAS  Google Scholar 

  10. Paik S, Hazan R, Fisher ER, DenBesten L, Longmire WP Jr. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projectaprognostic significance oferbB-2 protein overexpression in primary breast cancer.J Clin Oncol 1990; 8: 103–112

    PubMed  CAS  Google Scholar 

  11. Paterson MC, Dietrich KD, Danynuk J. Correlation between c-erbB-2 amplification and risk of recurrent disease in nodenegative breast cancer.Cancer Res 1991; 51: 555–567.

    Google Scholar 

  12. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. p185neuexpression in human lung adenocarcinomas predicts shortened survival.Cancer Res 1990; 50: 5184–5191.

    PubMed  CAS  Google Scholar 

  13. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. The c-erbB-2 proto-oncogene in human pancreatic cancer.J Pathol 1990; 161: 195–200.

    Article  PubMed  CAS  Google Scholar 

  14. Yamanaka Y, Friess H, Kobrin MS, Buchler M, et al. Overexpression of HER-2/neu oncogene in human pancreatic carcinoma.Human Pathol 1993; 24: 1127–1134.

    Article  CAS  Google Scholar 

  15. Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer.J Nippon Med Sch 1992; 59: 51–61.

    CAS  Google Scholar 

  16. Williams TM, Weiner DB, Greene MI, Maguire HC. Expression of c-erbB-2 in human pancreatic adenocarcinomas.Pathobiology 1991; 59: 46–52.

    Article  PubMed  CAS  Google Scholar 

  17. Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedure.J Histochem Cytochem 1981; 29: 577–580.

    PubMed  CAS  Google Scholar 

  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation.Am Stat Assoc 1984; 38: 511.

    Google Scholar 

  19. Bargmann CI, Hung MC, Weinberg RA. Theneu oncogene encodes an epidermal growth factor receptor-related protein.Nature (London) 1986; 319: 226–229.

    Article  CAS  Google Scholar 

  20. Holmes WE, Sliwkouski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2.Science 1992, 256: 1205–1210.

    Article  PubMed  CAS  Google Scholar 

  21. Berchuck A, Kemel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.Cancer Res 1990; 50: 4087–4091.

    PubMed  CAS  Google Scholar 

  22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science (Wash, DC) 1987;235: 177–182.

    Article  CAS  Google Scholar 

  23. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.Cancer Res 1989; 49: 2087–2090.

    PubMed  CAS  Google Scholar 

  24. Tyson FL, Soper JT, Daly L, et al. Overexpression and amplification of the c-erbB-2 (HER2/neu) proto-oncogene in epithelial ovarian tumors and cell lines.Proc Am Assoc Cancer Res 1988; 29: 471.

    Google Scholar 

  25. Slamon DJ, Godolphin W, Jones LA, et al. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer.Science (Wash, DC) 1989; 244: 707–712.

    Article  CAS  Google Scholar 

  26. Wido TM, Myles JL, Pisharodi L, Sawyer T, Kim K, Gohara AF, Howard JM. Aneuploid DNA content in pancreatic adenocarcinoma.Int. J. Pancreatol. 1990; 7: 129–134.

    PubMed  CAS  Google Scholar 

  27. Allison DC, Bose KK, Hruban RH, Piantadosi S, Dooley WC, Boitnott JK, Cameron JL. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy.Ann Surg 1991; 214: 648–656.

    Article  PubMed  CAS  Google Scholar 

  28. Bacus SS, Bacus JW, Slamon DJ, Press MF. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.Arch Pathol Lab Med 1990; 114: 164–169.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Pathology, Medical College of Ohio, and Toledo and Mercy Hospitals, 3454 Oak Alley Court, Suite 202, 43606, Toledo, OH

    Shize Lei, Hubert E. Appert, Bunzo Nakata, Don R. Domenico, Kitai Kim & John M. Howard

Authors
  1. Shize Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hubert E. Appert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bunzo Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Don R. Domenico
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kitai Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John M. Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lei, S., Appert, H.E., Nakata, B. et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 17, 15–21 (1995). https://doi.org/10.1007/BF02788354

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02788354

Key Words

Search

Navigation